Indications for Tirzepatide:

Tirzepatide was approved by the U.S. FDA in May 2022 for improving blood glucose in adults with type 2 diabetes mellitus and approved by the U.S. FDA in November 2023 to be marketed as a weight loss medication for adults who are obese (BMI of 30 and above) or overweight (BMI of 27 or above with at least one weight-related comorbid condition such as high blood pressure, type 2 diabetes, or high cholesterol) Weight loss, weight management along with lowering dietary calories and increasing exercise.

Pharmacologic effects of Tirzepatide:

Tirzepatide is a novel glucagon-like peptide-1 receptor (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) dual-receptor tract agonist, administered once a week.GLP-1 and GIP both belong to the enteroglucagon, which is a polypeptide secreted by the mucous membrane of the human gastrointestinal tract.The former can bind with the receptor on the pancreatic islet cells and stimulate the secretion of insulin, which then produces a glucose-lowering effect, and it also can The former can bind to the receptors on pancreatic islet cells and stimulate insulin secretion, thus producing a hypoglycemic effect, as well as delaying gastric emptying and suppressing appetite, thus controlling body weight; while the latter has the functions of inhibiting gastric acid and pepsin secretion, stimulating insulin release, inhibiting gastric peristalsis and emptying, and can supplement the role of the GLP-1 agonist.

Limitations of Use:
Concomitant use with other teicoplanin-containing products or any GLP-1 receptor agonist is not recommended.
Safety and efficacy in combination with other products used for weight management have not been established.
Has not been studied in patients with a history of pancreatitis.
Not for use in patients with type 1 diabetes mellitus.

Dosage and Administration Precautions:

Administer the drug by subcutaneous injection. The recommended starting dose is 2.5 mg subcutaneously once weekly. after 4 weeks, increase to 5 mg subcutaneously once weekly. After at least 4 weeks from the current dose, increase the dose in 2.5 mg increments. The recommended maintenance dose is 5 mg, 10 mg, or 15 mg administered subcutaneously once weekly.Consider therapeutic response and tolerability when selecting the maintenance dose. The maximum dose is 15 mg subcutaneously once weekly. taken once weekly at any time of the day, with or without meals. Inject subcutaneously in the abdomen, thigh or upper arm. Rotate injection site with each injection.

Treatment of missed doses:

If a dose is missed, instruct the patient to make up the missed dose as soon as possible within 4 days (96 hours) of the missed dose.

If more than 4 days have elapsed, skip the missed dose and make up the next dose on a regularly scheduled date In each case, the patient may resume the regular weekly dosing regimen.

If necessary, the weekly dosing date may be changed as long as the interval between doses is at least 3 days (72 hours).

Dosage forms and specifications:

Injection: clear, colorless to slightly yellow solution available in prefilled single-dose pens containing 2.5mg/0.5mL, 5mg/0.5mL, 7.5mg/0.5mL, 10mg/0.5mL, 12.5mg/0.5mL, 15mg/0.5mL.

The information is from the Internet and is for reference only.